Our laboratory investigates the minor spliceosome (MiS), a distinct RNA splicing machinery that is increasingly activated in cancer, with the goal of translating this biology into new therapeutic and diagnostic strategies for prostate and breast cancer.
Our work combines mechanistic cancer biology with translational approaches to understand how minor spliceosome activity contributes to tumor growth, therapy resistance, and DNA damage repair. We are developing strategies to therapeutically target minor spliceosomal snRNAs and other MiS components, including tumor-directed approaches designed to selectively inhibit minor splicing in cancer cells.
In parallel, we investigate whether MiS snRNA expression and activity can serve as biomarkers of tumor progression, treatment response, and therapeutic vulnerabilities. Our long-term goal is to establish the minor spliceosome as a new class of therapeutic targets and molecular markers in cancer, translating fundamental RNA biology into clinically applicable strategies.
